We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Type 1 Diabetes Risk Reflected in Gut Microbiome

By LabMedica International staff writers
Posted on 06 Sep 2019
Type 1 diabetes mellitus (T1D) is an autoimmune disorder characterized by the destruction of insulin-producing ß-cells in the pancreas, resulting in a life-long dependence on exogenous insulin. More...
T1D is an autoimmune condition that can develop at any age.

According to recent estimates, there are 1.3 million adults in the USA living with diabetes. Although the causes of type 1 diabetes are not yet known, there are many risk factors for this metabolic condition. Genetic risk factors for T1D have been identified in over 50 diverse genetic loci, but the greatest genetic determinant of T1D remains the human leukocyte antigen (HLA) region.

A team of scientists including those from Linköping University (Linköping, Sweden) examined data available from the All Babies in Southeast Sweden (ABIS) study. They conducted the ABIS study with the aim of understanding why children develop conditions that primarily involve the immune system. The ABIS study contains data from questionnaires and biological samples on over 17,000 children born in 1997–1999. As part of the study, scientists collected biological samples "at birth, 1 year, 2–3 years, and 5–6 years of age." The samples included "blood, urine, stool, and hair."

To enable the comparison of different levels of HLA risk for developing T1D autoimmunity, subjects with available HLA genotype data were placed into one of four categories of risk based on their HLA genotype. DNA from each sample was extracted from ~200 mg of stool, using the E.Z.N.A Stool Extraction Kit. DNA used for subsequent polymerase chain reaction (PCR) was quantified and assessed for purity using a NanoDrop spectrophotometer. Amplicons from each sample were pooled and sequenced on the MiSeq platform.

The scientists reported that both the core microbiome and beta diversity differ with HLA risk group and genotype. In addition, protective HLA haplotypes are associated with bacterial genera Intestinibacter and Romboutsia. They found that children with a high genetic risk had a different composition in their gut microbiota and different gut microbiomes than children with a low risk. The authors concluded that the information gained from this type of cohort furthers our understanding of how HLA genetic risk drives changes in the gut microbiome and how genetics may be “setting the stage” for environmental triggers that ultimately lead to T1D autoimmunity. The study was published on August 9, 2019, in the journal Nature Communications.

Related Links:
Linköping University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.